Seven U.S. representatives—five Democrats and two Republicans—lauded the 340B program on the House floor Tuesday night during an hour of speeches organized by Rep. Abigail Spanberger (D-Va.) and co-hosted by Rep. John Rose (R-Tenn.).
The event was postponed twice before
…
Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.
The company, a specialty manufacturer with two high-priced drug products on the market, announced its policy in email notices to covered
…
Drug manufacturers AstraZeneca and Sanofi have asked a 340B administrative dispute resolution panel to dismiss the National Association of Community Health Centers’ claims that its members are being overcharged due to the companies’ denied or restricted 340B sales when health
…
Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
Florida-based e5
…
Pharmacy care services company OptumRx is requiring 340B covered entities to get its consent before they share OptumRx contract pharmacy claims data with drug manufacturers to satisfy manufacturers’ conditions on 340B pricing.
OptumRx—a part of information and health services business
…
A federal district court’s ruling last October that federal law requires drug manufacturers to deliver 340B purchased drugs to contract pharmacies conflicts with two other courts’ conclusions, “upsets the delicate statutory balance Congress struck, and raises serious constitutional problems,” drug
…
Safety net healthcare providers increasingly have turned to the states to address challenges to the 340B program, 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.
“In just four years, an
…
Many 340B hospitals “may not offer low-income patients financial assistance to access medicines and may use extraordinary collection actions, including but not limited to, liens, foreclosures, and civil actions when patients fail to pay bills,” a pharmaceutical-industry funded study released
…
Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last weekend in
…*Sign up for news summaries and alerts from 340B Report